(NBIX) Neurocrine Biosciences, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NBIX) Neurocrine Biosciences, Inc. Complete Analysis Pack
Neurocrine Biosciences’ Business Model, Simplified
Unlock the full strategic blueprint behind Neurocrine Biosciences, Inc.’s business model. This concise Business Model Canvas shows how the company creates value through neuroscience innovation, targeted therapies, and strong partnerships. Ideal for investors, analysts, and strategists who want actionable insight—download the full version to explore every building block.
Partnerships
AbbVie women’s health collaboration
AbbVie is Neurocrine Biosciences, Inc. women’s health licensing partner for 2 key assets, ORILISSA and ORIAHNN. The deal helps Neurocrine extend development, commercialization, and market access through AbbVie’s larger sales reach and payer access, which matters for scaling these therapies in a competitive U.S. market.
Xenon ion-channel collaboration
Xenon is one of Neurocrine Biosciences, Inc.'s named partners in ion-channel work, supporting neuroscience discovery and clinical programs. The collaboration helps broaden Neurocrine Biosciences, Inc.'s pipeline in seizure and other neurologic targets, with Xenon's Kv7-channel programs advancing a key mechanism in epilepsy research.
Voyager Therapeutics gene therapy alliance
Voyager Therapeutics is Neurocrine Biosciences, Inc.'s gene-therapy partner for advanced neuroscience work, adding AAV delivery and vector design know-how to the pipeline. The tie-up broadens Neurocrine Biosciences, Inc. beyond small molecules and supports higher-risk CNS programs, where delivery is often the main bottleneck.
Takeda pharmaceutical partnership
Takeda is listed by Neurocrine Biosciences, Inc. as a strategic partner, and the tie-up helps share R&D work across neuroscience and nearby fields. No public deal value was disclosed, but the partnership widens Neurocrine’s external innovation pipeline and helps lower single-company research risk.
- Shared neuroscience R&D
- External innovation access
- No public deal value disclosed
Heptares Idorsia BIAL Mitsubishi Tanabe alliances
Heptares Therapeutics, Idorsia Pharmaceuticals, BIAL, and Mitsubishi Tanabe Pharma are four named collaborators in Neurocrine Biosciences, Inc.’s partnership base. These alliances widen scientific and geographic reach, while supporting licensing, development, and possible regional commercialization.
- 4 named partners
- Licensing and development focus
- Regional commercialization potential
Neurocrine’s Partner Network Fuels R&D and Growth
Neurocrine Biosciences, Inc. leans on AbbVie, Xenon, Voyager Therapeutics, Takeda, Heptares, Idorsia, BIAL, and Mitsubishi Tanabe Pharma to extend R&D, licensing, and regional reach. These ties help spread development risk and add external science in women’s health, ion channels, and gene therapy.
| Partner | Role | Key point |
|---|---|---|
| AbbVie | Licensing | ORILISSA, ORIAHNN |
| Xenon | Discovery | Ion-channel programs |
| Voyager Therapeutics | Gene therapy | AAV delivery |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas showing how Neurocrine Biosciences creates value through specialty neuroscience drugs, partners, and a focused U.S. commercial strategy.
Customizable Excel Spreadsheet
Quickly spot how Neurocrine Biosciences eases patient care gaps with a one-page business model snapshot.
Reference Sources
Neurocrine Biosciences, Inc. Reference Sources provide a clear, credible trail that supports faster due diligence and smarter decision-making.
Activities
Drug discovery in neuroscience and endocrine disease
Neurocrine Biosciences uses drug discovery to find new mechanisms and differentiated compounds for neurological, endocrine, and psychiatric diseases, and this work seeds its pipeline. In 2024, the Company reported $2.36 billion in revenue and $719 million in R&D spend, showing how heavily it backs early-stage science.
Clinical development of 5 named candidates
Clinical development is a core activity for Neurocrine Biosciences, Inc., with 5 named candidates in active development: NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568. The pipeline spans epilepsy, essential tremor, major depressive disorder, anhedonia, and schizophrenia, so execution across trials, endpoints, and regulatory steps drives the model.
Commercialization of 4 marketed products
Neurocrine Biosciences commercializes 4 marketed products—INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN—through U.S. promotion, payer access, and lifecycle management. This execution turns FDA approvals into recurring revenue and protects share in movement disorders and women’s health.
Regulatory and lifecycle management
Neurocrine Biosciences, Inc. treats regulatory and lifecycle management as a core gatekeeper for filings, approvals, label expansion, and post-approval upkeep across marketed drugs and pipeline assets. In FY2025, this matters most for Ingrezza, which drives most revenue, so even small label gains or clean compliance can protect a multibillion-dollar franchise and support long-term growth.
- Drives FDA filings and approvals
- Supports label expansion and upkeep
- Protects Ingrezza-led revenue base
- Keeps pipeline assets compliant
Safety, manufacturing, and supply support
Neurocrine Biosciences, Inc. must keep strong safety tracking, quality control, and manufacturing oversight across a portfolio led by Ingrezza, which topped $2 billion in annual net sales in 2024. For chronic therapies, steady supply is critical, because any break can hit adherence, patient access, and brand trust fast.
- Maintains product quality and safety monitoring
- Supports uninterrupted supply for chronic use
- Protects access, adherence, and trust
Neurocrine’s Build-and-Launch Model Drives $2.36B Revenue
Neurocrine Biosciences centers on discovery, clinical development, and U.S. commercialization, with 5 active pipeline assets and 4 marketed products. FY2024 revenue was $2.36 billion and R&D spend was $719 million, showing a heavy build-and-launch model.
| Key activity | FY2024 data |
|---|---|
| R&D and trials | 5 active candidates; $719 million R&D |
| Commercial execution | 4 marketed products; $2.36 billion revenue |
Full Version Awaits
Business Model Canvas
This Neurocrine Biosciences, Inc. Business Model Canvas preview is a direct snapshot of the exact document you’ll receive after purchase. It is not a mockup or sample—what you see here is the same professionally formatted file delivered in full. After buying, you’ll get instant access to the complete version with all content included.
Resources
INGREZZA brand and VMAT2 inhibitor asset
INGREZZA is Neurocrine Biosciences, Inc.’s core cash engine: net product sales were about $2.0 billion in 2025, making it the company’s main commercial asset. The VMAT2 inhibitor brand also anchors Neurocrine Biosciences, Inc.’s lead position in tardive dyskinesia treatment, supporting most of its revenue base.
4 marketed medicines
Neurocrine Biosciences, Inc.'s key resources include 4 marketed medicines: INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN. These approved products give the Company diversified coverage across movement disorders, Parkinson's disease, and women's health, and they remain its main near-term revenue engine.
5 named clinical pipeline programs
Neurocrine Biosciences, Inc. lists 5 named clinical pipeline programs: NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568. These assets are the company’s next growth options, but their value still depends on clinical success, regulatory wins, and eventual launch timing.
That makes the pipeline a key resource with binary risk: one setback can erase value, while one approval can add meaningful future revenue.
Strategic licensing and collaboration network
Strategic licensing and collaboration network is a key resource for Neurocrine Biosciences, Inc.: alliances with AbbVie, Xenon, Voyager, Takeda, Heptares, Idorsia, BIAL, and Mitsubishi Tanabe give access to 8 external science links, regional reach, and shared development risk, which helps widen innovation output without carrying the full R&D load alone.
- 8 partner links expand science access
- Shared risk lowers pipeline burden
- Regional deals support market reach
San Diego headquarters and neuroscience expertise
Neurocrine Biosciences, Inc., founded in 1992 and based in San Diego, California, relies on its scientific, clinical, and commercial teams as core resources. That in-house neuroscience know-how helps it keep drug programs moving from discovery to launch.
- Founded in 1992
- San Diego, California headquarters
- Scientific, clinical, commercial teams drive execution
Neurocrine’s $2B INGREZZA Sales Power a Strong R&D Engine
Neurocrine Biosciences, Inc.’s key resources are its commercial base and R&D engine: INGREZZA delivered about $2.0 billion of 2025 net product sales, while 4 marketed drugs and 5 named pipeline programs support near-term cash flow and future growth. Its 8 partner links with AbbVie, Xenon, Voyager, Takeda, Heptares, Idorsia, BIAL, and Mitsubishi Tanabe add science, reach, and risk sharing.
| Key resource | Latest data |
|---|---|
| INGREZZA sales | $2.0B in 2025 |
| Marketed drugs | 4 |
| Pipeline programs | 5 |
| Partners | 8 |
Value Propositions
INGREZZA for tardive dyskinesia
INGREZZA is Neurocrine Biosciences, Inc.'s flagship therapy for tardive dyskinesia, a disorder that affects up to 30% of patients exposed to antipsychotics. Its VMAT2 mechanism gives clinicians a targeted, once-daily option in a hard-to-treat movement disorder, and it remained the company’s main growth engine in 2025.
ONGENTYS adjunct therapy for Parkinson’s disease
ONGENTYS is a once-daily 50 mg oral add-on used with levodopa and a DOPA decarboxylase inhibitor, helping adults with Parkinson’s disease reduce OFF time and improve motor control. In the U.S., the label covers patients needing better symptom control, and Neurocrine reported ONGENTYS net product sales of $115.4 million in 2025.
ORILISSA for endometriosis pain
ORILISSA (elagolix) is approved for moderate to severe endometriosis pain and gives women a non-surgical option, which matters in a condition that affects about 190 million women worldwide and roughly 1 in 10 women of reproductive age.
For Neurocrine Biosciences, Inc., it targets a large women’s health need with a proven Rx therapy that can reduce pain without surgery.
ORIAHNN for fibroid-related heavy menstrual bleeding
ORIAHNN gives premenopausal women with fibroid-related heavy menstrual bleeding an oral, non-surgical option, cutting dependence on procedures like hysterectomy or myomectomy. This matters in a large market: uterine fibroids affect up to 80% of women by age 50, and heavy menstrual bleeding is a top symptom driving care decisions.
- Oral, medication-based alternative
- Targets fibroid-related heavy bleeding
- Differentiated women’s health option
5-program neuroscience pipeline
Neurocrine Biosciences, Inc. has a 5-program neuroscience pipeline spanning epilepsy, essential tremor, major depressive disorder, anhedonia, and schizophrenia. That gives it upside beyond 2025 net product sales of about $2.4 billion and supports a move from one-portfolio reliance to a broader multi-therapeutic model.
- 5 programs
- 5 disease areas
- Upstream growth beyond current brands
- Multi-therapeutic neuroscience reach
Neurocrine’s $2.4B Sales and 5-Program Pipeline Drive Growth
Neurocrine Biosciences, Inc. sells neuroscience and women’s health therapies that treat chronic, hard-to-manage diseases with oral, targeted options. In 2025, net product sales were about $2.4 billion, led by INGREZZA, while the company advanced a 5-program pipeline for future growth.
| Value driver | 2025 data |
|---|---|
| Net product sales | $2.4 billion |
| Pipeline programs | 5 |
| Lead brand | INGREZZA |
Customer Relationships
Specialist-led prescriber support
Neurocrine Biosciences, Inc. sells mainly through 3 specialist channels: neurologists and movement-disorder doctors, psychiatrists, and OB-GYNs. That makes clinical education a core part of the relationship model, since adoption depends on prescribers understanding dosing, safety, and patient selection across its specialty portfolio.
Patient support and adherence programs
Neurocrine Biosciences, Inc.’s chronic therapies need ongoing patient support, because once-daily use and long treatment cycles make onboarding, refill reminders, and persistence programs critical. That kind of adherence help keeps patients on therapy longer and supports repeat use of brands like INGREZZA and ONGENTYS.
Access and reimbursement management
Access and reimbursement management is central for Neurocrine Biosciences, Inc. because specialty drugs depend on payer coverage, prior auth, and formulary placement to get patients started fast and keep them on therapy. In 2024, Neurocrine generated $2.36 billion in total revenue, so even small access delays can affect meaningful sales and patient persistence.
Medical affairs and safety communication
Neurocrine Biosciences, Inc. keeps tight medical affairs and safety communication around its CNS and endocrine therapies, with teams helping clinicians use evidence-based dosing and monitor adverse events. That matters in chronic care, where long-term adherence and safety reviews shape outcomes more than one-time prescribing.
- Ongoing efficacy and safety dialogue
- Medical teams support evidence-based use
- Fits chronic neurologic and endocrine care
Long-term disease management relationships
Neurocrine Biosciences, Inc. serves chronic, recurring diseases, so its customer ties are built for years, not months. INGREZZA, used for tardive dyskinesia and Huntington’s chorea, and CRENESSITY, for congenital adrenal hyperplasia, both support long-term use, which makes steady trust with patients and physicians essential.
- Chronic diseases drive repeat use.
- Long therapy needs strong adherence support.
- Trust with doctors shapes persistence.
Neurocrine’s Revenue Depends on Fast Access and Adherence Support
Neurocrine Biosciences, Inc. builds customer ties around specialist prescribers, payer access, and long-term adherence support. In 2024, it generated $2.36 billion in revenue, so fast prior auth, formulary access, and safety follow-up directly shape sales and persistence.
| Key signal | Data |
|---|---|
| 2024 revenue | $2.36 billion |
| Core relationship need | Specialist education |
| Patient support | Refill and adherence help |
| Payer focus | Coverage and prior auth |
Channels
Neurology and psychiatry specialists
Neurology and psychiatry specialists are the core prescribers for INGREZZA, which has 2 FDA-approved CNS uses: tardive dyskinesia and chorea linked to Huntington’s disease. Neurocrine leans on field clinical detailing and specialist education, so this channel fits its neuroscience-first model and pipeline focus.
OB-GYN and women’s health specialists
OB-GYNs and women’s health specialists are a core channel for Neurocrine Biosciences, Inc.’s endocrine portfolio: ORILISSA and ORIAHNN depend on their diagnosis, prescribing, and follow-up decisions. Endometriosis affects about 1 in 10 women of reproductive age, so this specialist network is the main path to treatment and a major driver of sales.
Specialty pharmacies
Specialty pharmacies are a core channel for Neurocrine Biosciences, Inc. because they handle complex, chronic branded therapies like Ingrezza, including access checks, refill timing, and patient support; specialty drugs now account for about 50% of U.S. drug spend while making up under 2% of prescriptions. This channel helps keep starts and refills on track when prior auth and ongoing services matter most.
Wholesalers and distributors
Neurocrine Biosciences, Inc. moves its commercial products through standard pharmaceutical wholesalers and distributors, which helps keep U.S. access broad and supply steady. This channel supports nationwide fulfillment for products like Ingrezza and helps reduce stock gaps across the care network.
- Broad U.S. product access
- Standard pharma distribution
- Supports consistent supply
Payers and health systems
Payers and health systems shape Neurocrine Biosciences, Inc. access because plans and integrated delivery networks decide formulary status, prior auth, and step edits. With 2024 revenue of $2.36 billion, mostly from INGREZZA, Neurocrine must show clear economic value to win coverage and keep patients on therapy.
- Coverage drives uptake.
- Utilization rules affect retention.
- Value proof supports negotiations.
How Neurocrine’s Key Channels Drive Growth
Neurocrine Biosciences, Inc. reaches patients mainly through neurology, psychiatry, OB-GYN, specialty pharmacy, wholesalers, and payers. This matters most for INGREZZA and women’s health brands, where specialist prescribing and coverage rules drive starts, refills, and persistence.
Specialty pharmacies and payers are the key gatekeepers: they manage prior auth, refill support, and formulary access. Neurocrine Biosciences, Inc. posted $2.36 billion in 2024 revenue, so channel access directly shapes growth.
| Channel | Role |
|---|---|
| Specialists | Prescribe core brands |
| Specialty pharmacies | Support access and refills |
| Payers | Set coverage rules |
Customer Segments
Adults with tardive dyskinesia
Adults with tardive dyskinesia are Neurocrine Biosciences, Inc.’s core INGREZZA customer base, and the need is often chronic because symptoms can persist and require long-term control. This segment anchors the commercial engine: INGREZZA delivered about $2.3 billion in net sales in 2024, showing how a focused adult TD base drives most of the value.
Parkinson’s disease patients on levodopa
ONGENTYS targets adults with Parkinson’s disease who take levodopa plus a DOPA decarboxylase inhibitor and still have motor fluctuations; these add-on users are typically managed by neurologists and movement-disorder specialists. In the U.S., about 1 million people live with Parkinson’s disease, and roughly 40% to 50% develop troublesome OFF time as disease advances.
Women with endometriosis pain
Women with moderate to severe endometriosis pain are ORILISSA’s core users, and the segment is large: endometriosis affects about 1 in 10 women of reproductive age, or roughly 190 million women worldwide. OB-GYNs usually diagnose and treat this group, making it a major women’s health market for Neurocrine Biosciences, Inc.
Premenopausal women with fibroid bleeding
Premenopausal women with fibroid bleeding are a core women’s health segment for ORIAHNN, which treats heavy menstrual bleeding linked to uterine fibroids with an oral, non-surgical option. Uterine fibroids affect up to 70% of women by age 50, and ORIAHNN serves patients who want to avoid surgery and keep treatment simple.
- Oral, non-surgical care
- Heavy menstrual bleeding relief
- Women’s health and gynecology market
Epilepsy, depression, and schizophrenia patients
Neurocrine Biosciences targets epilepsy, depression, and schizophrenia patients because these CNS markets are large and under-treated: epilepsy affects about 50 million people worldwide, major depressive disorder about 280 million, and schizophrenia about 24 million. Its pipeline also spans pediatric and adult focal epilepsy, rare pediatric epilepsy, essential tremor, and anhedonia, creating future commercial upside.
- High-need CNS patients with few durable options.
- Large global pools support long-term growth.
- Pediatric and adult epilepsy expands reach.
Neurocrine’s Core Markets: TD, Parkinson’s, Women’s Health, and CNS Growth
Neurocrine Biosciences, Inc. serves five main customer groups: adults with tardive dyskinesia, Parkinsons disease OFF-time patients, women with endometriosis pain, women with fibroid-related heavy bleeding, and future CNS patients in epilepsy and mood disorders. INGREZZA remains the largest base, with about $2.3 billion net sales in 2024.
| Segment | Need |
|---|---|
| TD adults | Long-term symptom control |
| Parkinsons | Reduce OFF time |
| WomenS health | Endometriosis and fibroids |
| Future CNS | Epilepsy and mood |
Cost Structure
R&D and clinical trial spending
R&D and clinical trials are Neurocrine Biosciences, Inc.'s biggest cost driver: the Company spent about $750 million on R&D in its latest reported year, reflecting costly drug discovery and multi-indication studies. These programs are long and complex, so spending stays high before any product reaches the market.
Sales and marketing expense
Commercializing four marketed products means Neurocrine Biosciences must fund a field force, payer access, and specialist education; those sales and marketing costs move with revenue, which topped $2 billion in 2025. In specialty markets, coverage support matters as much as promotion, so spend rises when launches and penetration accelerate.
Manufacturing and cost of goods sold
Neurocrine Biosciences, Inc.’s approved medicines need reliable GMP production, packaging, and distribution, so manufacturing and cost of goods sold are recurring costs that rise with volume. In its latest reported year, product sales were about $2.4 billion and cost of revenues about $0.2 billion, showing that scale still matters but unit economics remain strong.
License fees, milestones, and royalties
External partnerships can add upfront fees, development milestones, and sales royalties, so pipeline access becomes a recurring cost, not just R&D spend. For Neurocrine Biosciences, Inc., these collaboration terms can shift deal economics by millions at signing and then low-single-digit to mid-teen royalties on future product sales.
- Upfront cash for pipeline access
- Milestone payments on progress
- Royalties on future sales
Regulatory, compliance, and pharmacovigilance
Regulatory, compliance, and pharmacovigilance are fixed costs that rise as Neurocrine Biosciences, Inc. adds products and indications, because every approved therapy needs ongoing safety monitoring, reporting, and label upkeep. In 2024, Neurocrine Biosciences, Inc. spent about $1.40 billion on R&D plus SG&A, a cost base that helps protect approvals and the franchise.
- Mandatory safety monitoring
- Higher cost with each indication
- Protects approvals and revenue
Neurocrine’s cost base is R&D-heavy, with strong gross margin support
Neurocrine Biosciences, Inc.’s cost structure is driven by R&D, commercial launch spending, and manufacturing scale. In 2025, R&D was about $750 million, revenue was about $2.0 billion, and cost of revenues was about $0.2 billion, showing a heavy innovation base with strong gross margin support.
| Cost item | 2025 | Signal |
|---|---|---|
| R&D | $750M | Largest fixed driver |
| Revenue | $2.0B | Funds commercial scale |
| Cost of revenues | $0.2B | Low direct production burden |
Revenue Streams
INGREZZA net product sales
INGREZZA net product sales are Neurocrine Biosciences, Inc.'s main revenue engine, with 2024 net sales of about $2.16 billion. The drug is prescribed for tardive dyskinesia, and that steady prescription base makes it the company’s core monetization source.
ORILISSA net product sales
ORILISSA generates revenue from women’s health prescriptions for endometriosis pain, giving Neurocrine Biosciences, Inc. a non-neurology growth stream. In 2025, that mix helped support a broader revenue base, with Neurocrine Biosciences, Inc. reporting total revenue above $2 billion.
ORIAHNN net product sales
ORIAHNN net product sales add direct revenue from treating uterine fibroid symptoms in premenopausal women with heavy menstrual bleeding. In Neurocrine Biosciences, Inc. fiscal 2025 reporting, the brand kept supporting the endocrine franchise alongside the broader women’s health portfolio.
ONGENTYS net product sales
ONGENTYS (opicapone) adds revenue from Parkinson’s disease adjunct therapy, used with levodopa to help reduce OFF time. In Neurocrine Biosciences’ 2025 mix, it broadens the commercial portfolio beyond INGREZZA and keeps a second branded neurology revenue stream in play.
- Adjunct to levodopa-based treatment
- Supports Parkinson’s disease revenue
- Diversifies Neurocrine Biosciences’ sales base
Collaboration, royalty, and milestone revenue
Neurocrine Biosciences, Inc. uses collaboration, royalty, and milestone revenue to bring in non-product cash from licensing deals, so it can fund pipeline work and reduce reliance on one drug. In FY2025, this stream stayed a small add-on versus total revenue, which was driven mainly by product sales.
Upfronts and milestones add partner cash.
Royalties scale with partner sales.
Supports pipeline without extra dilution.
INGREZZA Drives Neurocrine’s Revenue Engine
Neurocrine Biosciences, Inc. earns most revenue from INGREZZA, which delivered about $2.16 billion in 2024 net sales and remained the core cash engine in fiscal 2025. ORILISSA, ORIAHNN, ONGENTYS, and collaboration, royalty, and milestone income add smaller but useful revenue streams that broaden the mix beyond one drug.
| Stream | FY2025 role |
|---|---|
| INGREZZA | Main revenue driver |
| Other brands | Portfolio support |
| Collab/royalties | Non-product cash |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.